In particular, we demonstrated that the SP1 inhibitor plicamycin and the EGR1 inhibitor ML264 had therapeutic effects on attenuating cardiac hypertrophy in an HCM mouse model, possibly by reversing fetal reprogramming. Here, SP1 is linked to cardiac hypertrophy.